Applied Sciences
| Open Access |
DOI: Marine-derived Sugars for Cancer Therapy: A New Wave in Natural Drug Discovery
Mohd Jari Hasan Rizvi , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow - 226028, India Aymma Athar , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow - 226028, India Aditi Singh , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow - 226028, IndiaAbstract
Polysaccharides sourced from marine environments (termed “marine sugars”)—notably fucoidan, chitosan, alginate, carrageenan, laminarin, and ulvan—exhibit natural bioactivity and beneficial material properties that make them attractive candidates for oncology drug delivery systems (DDS). Recent developments (2023-2025) indicate that receptor-targeted strategies, like P-selectin–fucoidan interactions, notably enhance transcytosis and promote deeper tumor infiltration. Simultaneously, stimuli-sensitive hydrogels and designed nanoparticles facilitate controlled, localized drug delivery, whereas innovative combined therapies effectively integrate these polysaccharide carriers with leading chemotherapy, radiotherapy, and immunotherapies. This review thoroughly integrates structural–functional relationships, key design strategies, significant preclinical results, production scaling, and vital safety considerations. Additionally, a strategic translational route for progressing marine-sugar DDS to clinical evaluation is outlined. Key translational challenges—including consistent material characterization, strict management of endotoxins and impurities, and clear structure–activity profiles for sulfation and molecular weight—are highlighted, along with suggested steps to connect laboratory findings to clinical applications.
Keywords
marine polysaccharides, fucoidan, chitosan, alginate, drug administration, cancer, selectin targeting, hydrogel
References
Carrasqueira, J., Bernardino, S., Bernardino, R., & Afonso, C. (2025). Marine-derived polysaccharides and their potential health benefits in nutraceutical applications. Marine drugs, 23(2), 60.
Cha, M., Yan, S., Zhang, Y., & Wang, P. (2025). Progress in the application of marine polysaccharide drug delivery systems in tumor immunotherapy: Multiple mechanisms and material forms. Marine Drugs, 23(10), 384.
FDA Access Information (2024). Premarket Notification 510(k) and Premarket Approval (PMA) clearances for polysaccharide-based topical devices. U.S. Food and Drug Administration.
Hsu, C. Y., Allela, O. Q. B., Hussein, A. M., Mustafa, M. A., Kaur, M., Alaraj, M., ... & Farhood, B. (2024). Recent advances in polysaccharide-based drug delivery systems for cancer therapy: a comprehensive review. Artificial cells, nanomedicine, and biotechnology, 52(1), 564-586.
Jeong, S., Lee, S., Lee, G., Hyun, J., & Ryu, B. (2024). Systematic characteristics of fucoidan: intriguing features for new pharmacological interventions. International Journal of Molecular Sciences, 25(21), 11771.
Jia, H., Li, Y., Zheng, Y., Wang, H., Zhao, F., Yang, X., ... & Man, C. (2025). Recent advances in fucoidan-based improved delivery systems: Structure, carrier types and biomedical applications. Carbohydrate Polymers, 352, 123183.
Li, B. K., Raziuddin, R., Tylawsky, D., Singhania, M., Becher, O., Heller, D. A., & Raju, G. P. (2025). SURG-01. Fucoidan nanoparticle encapsulation of targeted therapies facilitates BBB penetration and tumor-specific localization in DMG. Neuro-Oncology Pediatrics, 1(Supplement_1), wuaf001-252.
Liang, X., Sun, Y., Guo, Y., Liu, B., Gu, Y., & Gao, W. (2026). Dual-Functional Chitosan-Hyaluronic Acid Dialdehyde Nanoparticles for CD44-Targeted Bcl-2 siRNA Delivery and Photothermal Therapy in Bladder Cancer. Journal of Biotechnology.
Liu, T. C., Shih, C. J., & Chiou, Y. L. (2024). Oral administration of oligo fucoidan improves the survival rate, quality of life, and immunity in patients with lung cancer. Food & nutrition research, 68, 10-29219.
Lukova, P., Katsarov, P., & Pilicheva, B. (2023). Application of Starch, Cellulose, and Their Derivatives in the Development of Microparticle Drug-Delivery Systems. Polymers 15: 3615.
Pramanik, S., Singh, A., Abualsoud, B. M., Deepak, A., Nainwal, P., Sargsyan, A. S., & Bellucci, S. (2024). From algae to advancements: laminarin in biomedicine. RSC advances, 14(5), 3209-3231.
Silva, O. L. T., et al. (2024). Exploring the pharmacological potential of carrageenan. Marine Drugs, 22(6), 271–289.
Tamzi, N. N., Rahman, M. M., & Das, S. (2024). Recent advances in marine-derived bioactives towards cancer therapy. International Journal of Translational Medicine, 4(4), 740-781.
Tripathi, A., Pandey, V. K., Rustagi, S., Lai, W. F., & Samrot, A. V. (2025). Alginate-based NPs for targeted ovarian cancer therapy: Navigating current progress and biomedical applications. International Journal of Biological Macromolecules, 319, 145365.
Tylawsky, D. E., Kiguchi, H., Vaynshteyn, J., Gerwin, J., Shah, J., Islam, T., ... & Heller, D. A. (2023). P-selectin-targeted nanocarriers induce active crossing of the blood–brain barrier via caveolin-1-dependent transcytosis. Nature materials, 22(3), 391-399.
Xue, P., Yu, Z., Shang, Y., Liu, S., Zhang, M., Zhu, F., Xiao, J., Long, L., & Guo, C. (2026). Dual-targeted fucoidan-TPP nanoparticles delivery system potently inhibit breast cancer via mitochondrial dysfunction and cGAS-STING activation. Colloids and surfaces. B, Biointerfaces, 258, 115279. https://doi.org/10.1016/j.colsurfb.2025.115279.
Yao, W., Qiu, H. M., Cheong, K. L., & Zhong, S. (2022). Advances in anti-cancer effects and underlying mechanisms of marine algae polysaccharides. International Journal of Biological Macromolecules, 221, 472-485.
Download and View Statistics
Copyright License
Copyright (c) 2026 Mohd Jari Hasan Rizvi, Aymma Athar, Aditi Singh
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.